ABIONYX Pharma Management
Management criteria checks 4/4
ABIONYX Pharma's CEO is Cyrille Tupin, appointed in Sep 2019, has a tenure of 5.17 years. total yearly compensation is €278.85K, comprised of 79.1% salary and 20.9% bonuses, including company stock and options. directly owns 4.59% of the company’s shares, worth €1.98M. The average tenure of the management team and the board of directors is 5.2 years and 8.5 years respectively.
Key information
Cyrille Tupin
Chief executive officer
€278.8k
Total compensation
| CEO salary percentage | 79.1% |
| CEO tenure | 5.2yrs |
| CEO ownership | 4.6% |
| Management average tenure | 5.2yrs |
| Board average tenure | 8.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -€3m |
| Mar 31 2024 | n/a | n/a | -€3m |
| Dec 31 2023 | €279k | €221k | -€4m |
| Sep 30 2023 | n/a | n/a | -€4m |
| Jun 30 2023 | n/a | n/a | -€4m |
| Mar 31 2023 | n/a | n/a | -€4m |
| Dec 31 2022 | €289k | €210k | -€4m |
| Sep 30 2022 | n/a | n/a | -€5m |
| Jun 30 2022 | n/a | n/a | -€6m |
| Mar 31 2022 | n/a | n/a | -€6m |
| Dec 31 2021 | €649k | €200k | -€6m |
| Sep 30 2021 | n/a | n/a | -€5m |
| Jun 30 2021 | n/a | n/a | -€4m |
| Mar 31 2021 | n/a | n/a | -€3m |
| Dec 31 2020 | €711k | €200k | -€2m |
| Sep 30 2020 | n/a | n/a | -€2m |
| Jun 30 2020 | n/a | n/a | -€2m |
| Mar 31 2020 | n/a | n/a | -€59k |
| Dec 31 2019 | n/a | n/a | €2m |
| Sep 30 2019 | n/a | n/a | €925k |
| Jun 30 2019 | n/a | n/a | €1k |
| Mar 31 2019 | n/a | n/a | -€3m |
| Dec 31 2018 | €5m | €175k | -€6m |
Compensation vs Market: Cyrille's total compensation ($USD294.61K) is below average for companies of similar size in the German market ($USD474.54K).
Compensation vs Earnings: Cyrille's compensation has been consistent with company performance over the past year.
CEO
Cyrille Tupin (48 yo)
5.2yrs
Tenure
€278,848
Compensation
Sir Cyrille Tupin, CPA is Chief Executive Officer, General Manager and Director at ABIONYX Pharma SA since September 6, 2019. Mr. Tupin served as the Chief Financial and Administrative Officer at ABIONYX...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, GM & Director | 5.2yrs | €278.85k | 4.59% € 2.0m | |
| Independent Director | 5.8yrs | €29.25k | no data | |
| Administrative & Financial Director | no data | no data | no data | |
| Vice President of Clinical | no data | no data | no data | |
| Chief Medical Officer and Head of R&D | less than a year | no data | no data | |
| Chief Digital & Innovation Officer | no data | no data | no data |
5.2yrs
Average Tenure
67yo
Average Age
Experienced Management: 609's management team is seasoned and experienced (5.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, GM & Director | 5.2yrs | €278.85k | 4.59% € 2.0m | |
| Independent Director | 9.8yrs | €29.25k | no data | |
| Censor | 9.8yrs | no data | no data | |
| Chairman of Scientific Advisory Board | no data | €23.00k | no data | |
| Independent Director | 7.4yrs | €29.25k | no data | |
| Independent Director | 9.5yrs | €18.75k | no data | |
| Chairman of the Board | 5.3yrs | €22.05k | 12.54% € 5.4m |
8.5yrs
Average Tenure
54yo
Average Age
Experienced Board: 609's board of directors are considered experienced (8.5 years average tenure).